FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

NIAID awards $46.3 million in vax grants and contracts

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded two grants to vaccine makers for anthrax and hepatitis B vaccines, respectively. Emergent BioSolutions received a contract worth up to $28.7 million for its third generation anthrax vaccine. Dynavax Technologies, based in Berkeley, CA, received a portion of a five-year, $17.6 million grant.

Emergent's new contract expands upon development efforts being conducted under a contract awarded in September 2008. The featured vaccine in the deal is a combination of the company's BioThrax vaccine and immunostimulatory VaxImmune. With this new contract, the potential funding from the U.S. government for this third generation anthrax vaccine candidate increases to more than $58 million, according to a statement. Emergent has previously won contracts worth more than $400 million for its anthrax vaccines, but the program seemed to be in trouble recently as Congress considered axing $2 billion of Project Bioshield's $5.6 billion budget.

NIAID's other grant was awarded to Dr. Jacques Banchereau of the Baylor Institute of Immunology Research. Part of that grant will be spent on Dynavax Technologies' promising hepatitis B vaccine, Heplisav. After some initial issues, Heplisav has performed promisingly in trials.

"Heplisav...has already demonstrated an ability to protect certain patients, for example, the elderly and chronically ill who are normally less- or non-responsive to conventional vaccines," says Robert Coffman, Dynavax's chief scientific officer, in a release. "With this grant we have the opportunity to study the underlying mechanisms that affect a target population's ability to respond to immunization."

- read the Emergent release
- and here's the Dynavax announcement
- check out the Washington Business Journal's article

Related Articles:
Project BioShield's vax programs on the chopping block
Emergent wins $404M anthrax vax contract
Dynavax shares spike on promising Heplisav data
Dynavax gets green light to resume hep B vax program


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Emergent BioSolutions   Dynavax   Heplisav   NIAID   anthrax vaccine  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.